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Abstract 41 
The branched-chain amino acids (BCAA) leucine, isoleucine and valine, are essential amino acids that 42 
play a critical role in cellular signalling and metabolism. They acutely stimulate insulin secretion and 43 
activate the regulatory serine/threonine kinase mammalian target of rapamycin complex 1 44 
(mTORC1), a kinase that promotes increased β-cell mass and function. The effects of BCAA on 45 
cellular function are dependent on their active transport into mammalian cells via amino acid 46 
transporters and thus the expression and activity of these transporters likely influences β-cell 47 
signalling and function. In this report we show that the System-L transporters are required for BCAA 48 
uptake into clonal β-cell lines and pancreatic islets and that these are essential for signalling to 49 
mTORC1. Further investigation revealed that the System-L transporter LAT1 is abundantly expressed 50 
in islets and that knock-down of LAT1 using siRNA inhibits mTORC1 signalling, leucine-stimulated 51 
insulin secretion and islet cell proliferation. In summary, we show that the System-L transporter 52 
LAT1 is required for regulating β-cell signaling and function in islets and thus may be a novel 53 
pharmacological/nutritional target for the treatment and prevention of type-2 diabetes. 54 
 55 
Introduction. 56 
The branched-chain amino acids (BCAA), leucine, isoleucine, and valine, are essential amino acids 57 
that play an important role in glucose homeostasis. In vitro, leucine stimulates insulin secretion 58 
(Newsholme et al. 2007) and improves insulin secretory function of human islets (Yang et al. 2006). 59 
Studies on the effect of diets containing increased BCAA or leucine on glucose homeostasis in vivo 60 
have been contradictory, likely due to differences in diet regimens and models. However, there is 61 
evidence that high protein diets, a source of BCAA, or leucine supplementation enhances insulin 62 
secretion and  glucose clearance in healthy adults and type-2 diabetics (Linn et al. 1996; van Loon et 63 
al. 2003; Kalogeropoulou et al. 2008; Leenders & van Loon 2011). Moreover, human neonates fed 64 
high protein formula milk have significantly raised serum leucine which parallels increased C-peptide 65 
(Socha et al. 2011).  66 
Branch chain amino acids, and particularly leucine, are also critical for the activation of mammalian 67 
target of rapamycin complex 1 (mTORC1) as they promote the translocation of mTORC1 to GTP-68 
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loaded Rheb, its upstream activator located at the lysosome (for review see (Bar-Peled & Sabatini 69 
2014)).  This process is dependent on a complex of proteins including Rags (Ras-related GTPases) , 70 
the Ragulator,  v-ATPase, GATOR (GAP activity towards Rags), and folliculin. Yet how changes in the 71 
amino acid concentration are sensed is still unclear. Although there is growing evidence to suggest 72 
that changes in the intra-lysosomal concentration play a significant role. Importantly, mTORC1 is a 73 
kinase whose hyperactivation in mice has been shown to stimulate both pancreatic β-cell function and 74 
mass (for reviews see (Blandino-Rosano et al. 2012; Xie & Herbert 2012)).  For example, β-cell 75 
specific deletion of tuberous sclerosis complex-2 (Tsc2), a negative regulator of mTORC1, or β-cell 76 
specific expression of constitutively-active Rheb, a small G protein which binds to and activates 77 
mTORC1, results in increased β-cell mass due to increased proliferation and cell size (Rachdi et al. 78 
2008; Balcazar et al. 2009). Mice expressing constitutively-active PKB in β-cells also have increased 79 
β-cell mass due to increased mTORC1 activity (Elghazi et al. 2007). Therefore, BCAA dependent 80 
activation of mTORC1 may be important in β-cell compensation and hence in protecting against the 81 
development of type-2 diabetes.  82 
The effects of amino acids on β-cell signaling, function and mass are likely mediated through 83 
changes in their intracellular concentration. Importantly, amino acid transporters play an important 84 
part in determining the size and composition of the intracellular amino acids pool. There are several 85 
amino acid transporter Systems facilitating transport of BCAAs including System B0,+, System y+L 86 
and System b0,+** and System-L (Hyde et al. 2003).  The System-L amino acid transporters (LATs) 87 
are high-affinity transporters of large neutral amino acids (i.e. the BCAA and aromatic amino acids) 88 
that are competitively inhibited by 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), a non-89 
metabolisable analogue of L-leucine. There are four members of this group called large neutral amino 90 
acid transporters or LATs. LAT1 and 2 are heterodimeric and are composed of a ‘light subunit’  that 91 
serves as an amino acid permease and a ‘heavy subunit’:  glycoprotein CD98 (cluster of 92 
differentiation 98) protein (encoded by SLC3A2) aka 4F2hc (4F2 cell-surface antigen heavy chain), 93 
that facilitates translocation of LAT to the plasma membrane (Verrey 2003). In contrast LAT3 and 94 
LAT4 are made up of a single subunit and doesn’t require CD98 for transport activity (Bodoy et al. 95 
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2005). Surprisingly, the amino acid transporter/s responsible for the uptake of BCAA into β-cells has 96 
remained largely unexplored. Moreover, their potential role in regulating mTORC1 activity and β-cell 97 
function are essentially unknown. In this report we demonstrate that System-L transporters are 98 
required for signalling to mTORC1 in β-cells. We also show that LAT1 is the most predominately 99 
expressed transporter in islets and that this transporter plays an important role in regulating both β-cell 100 
signalling and function. 101 
 102 
Materials and Methods 103 
Chemicals and media. All chemicals and media were purchased from Sigma-Aldrich (St. Louis, MO, 104 
USA) otherwise stated. EBSS (Earle’s Balanced Salt Solution) contained 20mM glucose, 2mM L-105 
glutamine, P/S/N (50 µg/ml streptomycin, 50 units/ml penicillin sulphate and 0.1mg/ml Neomycin) 106 
and the pH adjusted to 7.4 using NaHCO3. 1x MEM essential amino acids solution was made from a 107 
50X MEM stock (Sigma M5550) and contained 0.1264g/l L-Arg•HCl; 0.03128g/l L-Cys•2HCl; 108 
0.042g/l L-His HCl•H2O; 0.0525g/l L-Ile; 0.0524g/l L-Leu: 0.0725g/l L-Lys•HCl; 0.0151g/l L-Met; 109 
0.033g/l L-Phe; 0.0476g/l L-Thr; 0.0102g/l L-Typ; 0.036g/l L-Tyr; 0.0468g/l L-Val. 1x MEM 110 
essential amino acid mixture without System-L amino acids was made using individual amino acids 111 
purchased from Sigma and contained 0.1264g/l L-Arg•HCl; 0.03128g/l L-Cys•2HCl; 0.042g/l L-His 112 
HCl•H2O; 0.0725g/l L-Lys•HCl; 0.0151g/l L-Met; 0.0476g/l L-Thr. DMEM minus leucine media 113 
was made in-house from its constituent components.  114 
 115 
Cell culture and treatment. Rat insulinoma 1E (INS1E)  cells (Merglen et al. 2004) were maintained 116 
in a humidified incubator (95% air, 5% CO2) at 37°C in RPMI 1640 medium containing 11.1mM 117 
glucose, supplemented with 5% (v/v) heat inactivated fetal bovine serum (FBS) (Invitrogen, Thermo 118 
Scientific Inc, Waltham, MA USA), 1mM sodium pyruvate, 10mM HEPES, 55µM β-119 
mercaptoethanol, P/S/N (50 µg/ml streptomycin, 50 units/ml penicillin sulphate and 0.1mg/ml 120 
Neomycin). Prior to treatments, INS1E cells were serum starved overnight (16h) in CMRL-1066 121 
medium containing 0.5mM L-glutamine and  P/S/N. Cells were treated as described in the figure 122 
legends.  123 
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Pancreatic islets were isolated from Male Wistar Albino rats weighing 200g-250g and dissociated as 124 
previously described (Moore et al. 2011). The dispersed cells were plated on a poly-D-lysine coated 125 
plates and incubated in RPMI-1640 media containing 10% FBS and P/S/N. Cells were treated as 126 
described in the figure legends.  127 
 128 
SDS- Polyacrylamide Gel Electrphoresis and Western Blot Analysis. 129 
SDS-page and Western blotting were performed as previously described (Moore et al. 2009) using 130 
anti-phospho Akt/PKB (Ser473), anti-Akt/PKB, anti-phospho S6K1(Thr389), anti-phospho ribosomal 131 
protein S6 (Ser240 /244) and anti-LC3 A/B from Cell signalling Technologies, Beverly, MA, USA, 132 
and anti-ribosomal protein S6 obtained from Santa Cruz Biotechnology Inc, Santa Cruz, CA USA. 133 
 134 
Amino Acid Analysis. 135 
Amino Acid analysis was performed essentially as previously described (Evans et al. 2007). After 136 
treatments, INS1E or islets of Langerhans were rapidly chilled on ice, rinsed three times with ice-cold 137 
1x PBS to remove extracellular amino acids, and deproteinized by scraping with 150µl of 0.3M 138 
perchloric acid. The resulting lysate was transferred to microcentrifuge tubes on ice, followed by 139 
incubation for at least 30 min. Precipitated protein was sedimented by centrifugation (10min, 4°C, 140 
14000g) and retained for total protein assay. Supernatant was filtered through a 0.45μm microfilter 141 
and was immediately used for determination of amino acids on an Agilent 1100 high-performance 142 
liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA)  with Zorbax Eclipse AAA 143 
column (4.6 x 75mm, 3.5µm) at 40°C with o-phthalaldehyde/3-mercaptopropionate/9-144 
fluorenylmethylchloroformate precolumn derivatization and ultraviolet and fluorimetric postcolumn 145 
detection.  146 
 147 
RNA isolation of qRT-PCR 148 
peqGOLD Total RNA Kit (VWR international, Germany) was used in RNA extraction for qRT-PCR 149 
according to manufacturer’s protocol. Islets of Langerhans were cultured for 2 days prior to RNA 150 
extraction. 2µg of total RNA from each extraction was used as template for reverse-transcription 151 
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using SuperScriptTM VILO cDNA synthesis kit (Invitrogen). qRT-PCR was then performed on cDNA 152 
from 1ng RNA using gene-specific primers from PrimerDesign (Southampton, UK): Rat LAT1 153 
forward 5´-TTGTTCGTTCAGTAGCACATTG-3´ and reverse 5´-ATTCATCGTCCGTTTGTCAGT-154 
3´; Rat LAT2 forward 5´-CCAGTTCCTCTCCCCTCCT-3´ and reverse 5´-155 
CAAAGTGAGTGCCATCCTGTC-3´; Rat LAT3 forward 5´-ACACTGAAGTTTTGTCTCCGTTG-156 
3´ and reverse 5´-TTGGGCAGAGTAAGTGAGGTAAA-3´; Rat LAT4 forward 5´-157 
CAGAAGCGAGACAGGCAGAT-3´ and reverse 5´-TGTAGAGGCAGATTAGGAATGAGG-3´;  158 
and 18s RNA primers forward 5´- GTTGGTTTTCGGAACTGAGG -3´ and reverse 5´- 159 
GCATCGTTTATGGTCGGAAC -3´.  160 
 161 
Transfection of siRNAs 162 
Rat islets of Langerhans were dispersed in a 24-well plate and cultured overnight in rat islet growing 163 
medium prior to transfection using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM® medium 164 
(Invitrogen) according to the manufacturer’s instructions. For LAT1 knock-down, the cells were 165 
transfected for 72h with 100nM on-target plus siRNA (Dharmacon) against SLC7A5 (L-092749-01-166 
0005), or 100nM Silencer® Select Pre-Designed siRNA (Invitrogen) against SLC7A5 (s132356).  167 
 168 
Proliferation Assay 169 
Rat islet cell proliferation assays were performed essentially as previously described (Kwon et al. 170 
2006; Xie et al. 2014). 150 rat islets of Langerhans per treatment were used for proliferation assay. 171 
Islet cells were starved in RPMI media supplemented with 0.2% FBS and treated with 172 
DMEM+16.7mM glucose in the absence or presence of 0.8mM L-Leucine or 2.5mM BCH for 48 h. 173 
2μCi/ml [3H]-thymidine was added during the last 24h. Cells were then collected and washed twice 174 
with 1X Phosphate Buffered Saline (PBS). DNA was precipitated on ice upon the addition of 5% 175 
trichloroacetic acid for 30min. Samples were spun at 16000 x g, 4°C for 10min and DNA pellets were 176 
then solubilised by adding 0.1N NaOH and incubated for 30min at RT. [3H]-thymidine incorporation 177 
was determined by quench-corrected scintillation counting using the LS6500 multi-purpose 178 
scintillation counter to detect DPM (disintegrations per minute) in each sample. 179 
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 180 
Leucine transport assays.  181 
Cells were preincubated for 10 min in the culture incubator in Leucine-free Krebs Ringer Buffer 182 
(KRB). L-[4,5-3H]-leucine (Perkin Elmer) plus unlabelled L-Leucine were then added to the KRB to 183 
give a final radio-isotope concentration of 5µCi/ml and a final total L-Leucine concentration of 184 
0.8mM. BCH was also added to some cultures to give a final concentration of 2.5mM. Cultures with 185 
3H were then incubated in the culture incubator for exactly 5 min. The cells were then immediately 186 
placed on ice, the medium aspirated off, and the cells rapidly washed 3x in ice-cold KRB. 0.05M 187 
NaOH was then added to the cells and the lysates transferred to microcentrifuge tubes. The lysates 188 
were then incubated at 70oC for 30 min. A fraction of the lysate was then transferred to a scintillation 189 
vial containing Ecoscint A scintillant and allowed to stand for at least an hour to allow 190 
chemiluminescence to decay before quench-corrected scintillation counting using the LS6500 multi-191 
purpose scintillation counter. L-[4,5-3H]-leucine transport rate is expressed as DPM / mg protein / 5 192 
min. 193 
 194 
Insulin Secretion Assay. 195 
Following treatments, the test media were collected and centrifuged at 2000g for 3 min to pellet any 196 
detached cells. The supernatants were collected and the insulin concentrations measured using a Rat 197 
Insulin Enzyme Immunoassay Kit (Bertin Pharma, A05105-96 wells) with rat insulin as a standard in 198 
accordance with manufacturer’s instructions. The absorbance was read at 414nm on the NOVOstar 199 
microplate reader. 200 
 201 
Statistical Analysis. 202 
Results are expressed as means ± SEM. Data were analyzed by one-way analysis of variance, 203 
ANOVA, followed by Bonferroni correction for all pair-wise comparisons, or two-tailed paired T-test 204 
using GraphPad Prism 6.0. Significance was assigned at P< 0.05. 205 
 206 
Results and Discussion 207 
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 208 
System-L transporters are critical for mTORC1 activation in the rodent clonal pancreatic 209 
β-cell line INS1E.  210 
The System-L amino acid transporters are widely expressed and members of its family are 211 
capable of transporting large neutral amino acids including the BCAA. Therefore, we initially 212 
investigated the role of the System-L family of amino acid transporters in signalling to mTORC1 in β-213 
cells.  214 
Clonal rat pancreatic β-cells (INS1E cells) were treated with insulin to activate mTORC1, in the 215 
presence or absence of BCH (2-aminobicyclo-(2,2,1) heptanecarboxylic acid), a competitive inhibitor 216 
of System-L, or in the presence or absence of the System-L amino acids substrates: L-Leu, L-Ile, L-217 
Val, L-Phe, L-Tyr and L-Trp (Figure 1a). As anticipated, the addition of insulin led to a robust 218 
increase in mTORC1 activity as determined by the phosphorylation of its downstream target S6 219 
kinase 1 (S6K1) on Thr389 and a substrate of S6K1, ribosomal protein S6 (rpS6) on Ser240/244. 220 
Insulin also stimulated the activation of protein kinase B (PKB), as assessed by its phosphorylation on 221 
Ser473 (Figure 1a). The addition of BCH or the withdrawal of System-L substrates (i.e. L-Leu, L-Ile, 222 
L-Val, L-Phe, L-Tyr and L-Trp) significantly inhibitedinsulin-stimulated mTORC1 activation. In 223 
addition, BCH induced the conversion of cytosolic LC3-I to the lipid-bound LC3-II, which is widely 224 
used as the measurement of autophagic flux (Klionsky et al. 2008), indicating that BCH promotes 225 
autophagy, possibly through its inhibition of mTORC1 (Jewell et al. 2013). Interestingly, BCH also 226 
inhibited insulin-stimulated phosphorylation of PKB. In contrast, the withdrawal of System-L amino 227 
acids had no significant effect on the conversion of LC3 or on the phosphorylation of PKB. In 228 
summary, these results provide good evidence that the System-L transporters play a critical role in 229 
signalling to mTORC1 and may also influence autophagy and PKB activity.  230 
The effects of BCH and the removal of System-L substrates on cellular signalling are possibly 231 
mediated by a decrease in the intracellular concentration of BCAA. To investigate this, the effect of 232 
BCH or System-L AA withdrawal on the intracellular amino acids pool was determined by HPLC 233 
analysis (Figure 1b). System-L AA withdrawal led to a dramatic decrease in the intracellular 234 
concentration of the BCAA but had no significant effect on the intracellular concentration of the 235 
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aromatic amino acids, likely reflecting their low rate of catabolism. The addition of BCH caused a 236 
significant decrease in the intracellular concentration of leucine and a trend towards a decrease in the 237 
other BCAA, indicating the importance of System-L transporters in the uptake of BCAA in β-cells. 238 
To directly investigate the role of System-L transporters on BCAA transport into INS1E cells, the 239 
effect of BCH on [3H]-leucine uptake into INS1E cells was also determined (Figure 1c1e).  BCH 240 
caused a significant decrease in the uptake of [3H]-leucine, demonstrating that System-L transporters 241 
play an important role in BCAA uptake into INS1E cells.  242 
 243 
The uptake of L-leucine through System-L amino transporters is required for mTORC1 244 
activation. 245 
To determine which System-L amino acids are required for signalling to mTORC1, INS1E cells were 246 
depleted of System-L amino acids and the effect of the re-addition of each System-L amino acid in 247 
turn on the restoration of insulin signalling to mTORC1 was assessed (Figure 2a). The re-addition of 248 
L-Leucine significantly restored insulin signalling to mTORC1, whereas the re-addition of L-249 
Isoleucine, L-Valine, L-Phenylalanine, L-Tyrosine and L-Tryptophan had little-to-no effect on 250 
mTORC1. Thus, of the System-L substrates, only L-Leucine is able to restore insulin signalling to 251 
mTORC1. These results confirm and extend previous findings in the rat insulinoma cell line RINm5F 252 
and isolated rat islets (Xu et al. 1998) . 253 
To investigate whether L-Leucine-stimulated mTORC1 activation was indeed dependent upon 254 
System-L transporters, INS1E cells depleted of leucine were incubated with 0.8mM or 0.4mM L-255 
Leucine in the presence or absence of 10mM BCH (Figure 2b). As anticipated, the re-addition of 256 
leucine-stimulated mTORC1 activation as determined by the phosphorylation of S6K1 and rpS6. 257 
Surprisingly, leucine re-addition also inhibited the phosphorylation of PKB on S473 (Figure 2b). This 258 
is possibly mediated by a well characterised mTORC1-dependent feed-back mechanism in which S6K 259 
phosphorylates insulin receptor substrate and inhibits insulin signalling (Harrington et al. 2004; 260 
Tremblay et al. 2007). Importantly, in the presence of BCH, leucine-stimulated mTORC1 activation 261 
was inhibited. Moreover, BCH inhibited PKB and induced autophagy as assessed by the conversion 262 
of cytosolic LC3-I to the lipid-bound LC3-II (Figure 2b). 263 
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In order to define the EC50 of L-Leucine to activate mTORC1, INS1E cells preincubated in leucine-264 
free media, were treated for 30 min with increasing concentrations of L-Leucine (Figure 2c). L-265 
Leucine activated mTORC1 in a dose-dependent manner with EC50’s of 267µM and 227µM for 266 
S6K1 and rpS6 phosphorylation respectively, with a maximum response at approximately 2mM 267 
(Figure 2c). Nifedipine, an L-type VGCC inhibitor, is unable to block leucine-stimulated activation of 268 
mTORC1(figure 2d) and thus the effects of leucine on mTORC1 are not due to leucine-stimulated 269 
insulin secretion.  270 
To investigate the temporal regulation of mTORC1 activation upon leucine re-addition or withdrawal, 271 
INS1E cells were either depleted of leucine (Figure 3a) or leucine added to leucine-starved cells 272 
(Figure 3b) for up to 30 min and changes in PKB and mTORC1 activity determined (Figure 3). The 273 
phosphorylation of S6K1 at Thr389 and rpS6 rapidly decreased within 10min of L-Leucine 274 
withdrawal, and further decreased to an undetectable level by 15min (Figure 3a). The phosphorylation 275 
of PKB at Ser473 was also significantly decreased by 5min of L-Leucine withdrawal; however, by 276 
15min, PKB phosphorylation started to recover and returned to basal levels by 30min (Figure 3a). In 277 
addition, the conversion of LC3-I to LC3-II increased within 5min of L-Leucine withdrawal, 278 
indicating the induction of autophagy (Figure 3a). The re-addition of leucine to leucine-starved cells 279 
caused a rapid (within 5-10min) increase in mTORC1 activation as determined by the 280 
phosphorylation of S6K1 and rpS6 (Figure 3b). The phosphorylation of PKB at Ser473 also rapidly 281 
decreased but returned to basal levels by 30min (Figure 3b). In addition, the abundance of LC3-II 282 
rapidly decreased, indicating an inhibition of autophagy (Figure 3b). Given the rapidity of these 283 
events, we investigated whether these changes in mTORC1 activity correlated with changes in the 284 
intracellular leucine concentration (Figure 3c). The withdrawal of extracellular leucine for 10 min 285 
resulted in the depletion of intracellular leucine whereas within 10 min of its re-addition the 286 
intracellular concentration of leucine returned to basal levels (Figure 3c). Thus under these conditions 287 
changes in the extracellular concentration of leucine are rapidly mirrored by changes in their 288 
intracellular concentration, which reflect the activation state of mTORC1. 289 
 290 
System-L transporters are required for islet cell function and signalling to mTORC1. 291 
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Having established the importance of System-L transporters in clonal pancreatic β-cells, we wished to 292 
investigate their potential role in primary β-cells (figure 4). Therefore, islets of Langerhans were 293 
isolated from rats and deprived of leucine prior to the re-addition of the system-L substrate L-Leucine 294 
in the presence or absence of BCH (Figure 4a). The re-addition of L-Leucine significantly stimulated 295 
mTORC1, as determined by the phosphorylation state of S6K1 at Thr389 and rpS6 on S240/244, and 296 
reduced the phosphorylation of PKB at Ser473. The co-addition of BCH significantly inhibited 297 
leucine-stimulated mTORC1 activation and also induced autophagy as measured by the conversion of 298 
LC3-I to LC3-II (Figure 4a). These results are similar to that observed in INS1E cells (Figure 2). 299 
Leucine can also stimulate insulin secretion (Newsholme et al. 2007), so in order to ascertain the role 300 
of System-L transporters in leucine-stimulated insulin secretion, rat islets of Langerhans were 301 
incubated in leucine depleted media for 1h prior to addition of leucine for 30min in the presence or 302 
absence of BCH. As anticipated, leucine stimulated insulin secretion but this was significantly 303 
inhibited by the presence of BCH (Figure 4b), showing that leucine-dependent stimulation of insulin 304 
secretion is dependent upon System-L transport activity.  305 
As mTORC1 activation promotes β-cell proliferation (Xie et al. 2014) the role of System-L 306 
transporters on islet cell proliferation was also investigated. Dispersed islets were incubated in either 307 
in the absence of L-leucine or in the presence of BCH and islet cell proliferation was measured by the 308 
incorporation of [3H]-thymidine into DNA (Figure 4c). The addition of BCH or the removal of 309 
leucine significantly inhibited islet cell proliferation. Thus system-L transporter activity is required for 310 
islet cell proliferation. 311 
To investigate the effect of BCH or leucine withdrawal on the intracellular leucine concentration 312 
HPLC amino acid analysis was performed (figure 4d). The removal of leucine caused the depletion in 313 
leucine whereas its re-addition restored intracellular leucine concentration. The re-addition of leucine 314 
in the presence of BCH caused a significant decrease in the intracellular concentration of leucine 315 
indicating that leucine uptake is mediated by System-L transporter (Figure 4d). Moreover [3H]-leucine 316 
uptake into cells was significantly inhibited by BCH (figure 4e) providing further evidence that 317 
System-L transporters play a significant role in leucine transport into islets.  318 
 319 
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System-L transporter expression and function in islets of Langerhans. 320 
Having established that system-L transporters play a significant role in β-cell signalling, we 321 
wished to investigate which of the System-L transporters were likely responsible. There are four 322 
System-L amino acid: LAT1, LAT2, LAT3 and LAT4 encoded by SLC7A5, SLC7A8, SLC43A1 and 323 
SLC43A2 respectively (Kanai et al. 1998; Mastroberardino et al. 1998; Pineda et al. 1999; Segawa et 324 
al. 1999). In order to assess their relative expression in primary rat islets, qRT-PCR (quantitative real 325 
time polymerase chain reaction) was performed (Figure 5a).  LAT1, LAT2 and LAT4 were all 326 
expressed in islets, although LAT1 and LAT4 were found to be the most abundantly expressed 327 
System-L transporters. 328 
Both LAT1 and 2 are obligate heterodimers that require CD98 for function. Therefore, to inhibit 329 
the function of both LAT1 and 2 and not LAT3 and 4 the expression of CD98 was down regulated 330 
using siRNA (figure 5b).  Knockdown of CD98 caused a significant decrease in the activation of 331 
mTORC1 as determined by the phosphorylation of S6K. There was also a trend towards a decrease in 332 
both PKB and rpS6 phosphorylation but these changes proved statistically insignificant. Taken 333 
together these data would suggest that LAT1 likely plays a significant role in regulating mTORC1 in 334 
β-cells 335 
 336 
LAT1 plays an important role in islet signalling to mTORC1 in islets of Langerhans 337 
As LAT1 is abundantly expressed System-L transporter in islets and siRNA mediated knock-338 
down of CD98 inhibits mTORC1 (Figure 5), we focused on the role of LAT1 in islets. Two distinct 339 
siRNAs directed against the mRNA encoding LAT1 (slc7a5) (labelled LAT1-A and LAT1-B) were 340 
transfected into dispersed islet cells (Figure 6). The efficiency of LAT1 knockdown, as determined by 341 
qRT-PCR quantification, was approximately 41% and 59% using siRNA’s LAT1-A and LAT1-B 342 
respectively (Figure 6c and d). The knockdown of LAT1 expression using either siRNA had no 343 
detectable effect on cell morphology (unpublished observations) but caused a significant decrease in 344 
L-Leucine-stimulated phosphorylation of S6K1 at Thr389, demonstrating that LAT1 is required for 345 
mTORC1 activation (Figure 6a and b). It also consistently caused a decrease in the phosphorylation of 346 
rpS6 at Ser240/244; however this proved statistically insignificant. Interestingly the knock down of 347 
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LAT1 using siRNA LAT1-B significantly inhibited PKB phosphorylation. Although no statistically 348 
significant change in the phosphorylation of PKB was detected using siRNA-A, there was a trend 349 
towards a decrease in PKB phosphorylation.  350 
In conclusion, the System-L transporter LAT1 plays an important role in signalling to mTORC1 351 
and possibly PKB in islet cells.  352 
 353 
LAT1 plays an important role in islet function and proliferation in islets of Langerhans 354 
To investigate the role of LAT1 in islet function and proliferation the expression of LAT1 was 355 
knocked-down in dispersed islets of Langerhans using siRNA. siRNA mediated reduction in LAT1 356 
expression significantly inhibited leucine-stimulated insulin secretion (Figure 7a). Moreover, islet cell 357 
proliferation, as determined by the incorporation of [3H]-thymidine into DNA, was also significantly 358 
inhibited (Figure 7b). In conclusion, the System-L transporter LAT1 plays an important role in islet 359 
cell proliferation and insulin secretion. Although a reduction in LAT1 expression decreases mTORC1 360 
activation and others and we have shown that mTORC1 is required for β-cell proliferation  (Balcazar 361 
et al. 2009; Xie et al. 2014) it is difficult to confirm whether the effects of reducing LAT1 expression 362 
on proliferation is indeed mediated by the inhibition of mTORC1. However, these effects are unlikely 363 
due to the potential positive effects of leucine on insulin secretion as these experiments were carried 364 
out in nutrient rich media containing a high concentration of glucose.  365 
 366 
Discussion 367 
In this report we provide evidence that System-L transporters, and in particular LAT1, play a 368 
critical role in β-cell signalling to mTORC1, the maintenance of β-cell function and proliferation. 369 
LAT1 is highly expressed in rat, mouse and human  islets of Langerhans ((Figure 5) and (Fukushima 370 
et al. 2010; Nakada et al. 2014; Zhou et al. 2014)) and is also highly expressed in testicular sertoli 371 
cells, ovarian follicular cells and proximal to proliferative zones in the gastrointestinal mucosa 372 
(Nakada et al. 2014). In addition, LAT1 is widely expressed in non-epithelial cells showing its highest 373 
expression in endothelial cells forming the blood-brain barrier in the brain indicating that it is also 374 
important in transporting amino acids across endothelial/epithelial secretory barriers such as blood-375 
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brain barrier (Mastroberardino et al. 1998; Verrey 2003). As LAT1 expression is upregulated in a 376 
range of tumours and is widely expressed in foetal tissue, LAT1 is thought to be particularly 377 
important in transporting amino acids into highly proliferating cells (Nakada et al. 2014; Yanagisawa 378 
et al. 2014). As LAT1 is an obligate amino acid exchanger, its activity is not only governed by 379 
extracellular amino acid concentration but also by the intracellular amino acid concentration 380 
controlled by, for example, metabolism and the activity and expression of other amino acid 381 
transporters (Meier et al. 2002; Verrey 2003). These include the sodium dependent system A 382 
transporters, such as SNAT2, which transport small neutral amino acids such as glutamine and alanine 383 
which act as substrates for LAT1 to drive the transport of BCAA and aromatic amino acid into the 384 
cell (Evans et al. 2007). The reported Km of LAT1 for BCAAs is approximately 50-100µM whereas 385 
for leucine it is between 18-62µM (Meier et al. 2002). We show that the EC50 for leucine activation 386 
of mTORC1 in INS1E cells was approximately 200µM, well within the physiological relevant range 387 
of plasma leucine concentration, which is between 100-400 µM. The difference between the EC50 for 388 
leucine-stimulated mTORC1 activation and the Km for LAT1 could be due to factors independent of 389 
transport required for the activation of mTORC1 or they could be simply due to differences in cell 390 
systems and experimental conditions. Another possibility is that other amino acid transporters also 391 
play an important role in leucine uptake into β-cells, such as LAT4. LAT4 was also found to be highly 392 
expressed in islets (Figure 5) and this transporter has a Km of approximately 3mM for leucine (Bodoy 393 
et al. 2005). 394 
As the combined fasting concentration of System-L AA substrates is approximately 650µM 395 
(Bergstrom et al; Kidney Int. 1990), LAT1 is likely operating near saturation. Thus changes in the 396 
expression of LAT1 will increase BCAA uptake. LAT1 expression is upregulated by growth factors 397 
via activation of mTORC1 but also by ER stress, probably via ATF4 (Harding et al. 2003; Liu et al. 398 
2004; Wang et al. 2011a; Krokowski et al. 2013; Cnop et al. 2014). As β-cells undergo ER stress in 399 
the face of obesity and insulin resistance, it is possible that LAT1 expression is increased and that this 400 
in turn leads to increased mTORC1 activation and a compensatory increase in β-cell function and 401 
mass. Therefore, it is important to establish whether there are changes in LAT1 expression in β-cells 402 
during both the progression of obesity and type-2 diabetes.  403 
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Amino acid transporters have also been proposed to act as receptors that sense changes in the 404 
extracellular/intracellular amino acids concentration, possibly by monitoring amino acid flux through 405 
the transporter, to transduce an intracellular signal (Hundal & Taylor 2009). For example, SNAT2 has 406 
been proposed to act as a ‘transceptor’ and regulate PKB activity (Evans et al. 2007, 2008). 407 
Interestingly, BCH inhibited PKB activation. In addition, knock down of LAT1 also inhibited PKB 408 
activity. How System-L transporters influence PKB activity is unknown although it may be 409 
independent of the intracellular concentration of BCAA. Interestingly, the effects of BCH on 410 
signalling to mTORC1 and PKB are much stronger than that of amino acid withdrawal, despite the 411 
fact that amino acid withdrawal results in a greater effect on the intracellular level of leucine/BCAA. 412 
The reason for this is not entirely clear but a possible explanation is that signalling to mTORC1 and 413 
PKB is more responsive to the L-Leucine/transporter complex than it is to the free cytosolic L-Leu 414 
concentration (Hundal & Taylor 2009).  415 
 As BCAA can activate mTORC1, a kinase that stimulates increased pancreatic β-cell mass 416 
and function (for review see (Xie & Herbert 2012)), increased LAT1 expression or activity may be 417 
anti-diabetogenic. However, the chronic hyperactivation of mTORC1 inhibits insulin/growth factor 418 
signalling mediated by ribosomal protein S6 kinase (S6K) inhibitory phosphorylation of insulin 419 
receptor substrate (Um et al. 2004, 2006). Indeed, although β-cell specific mTORC1 gain-of-function 420 
mutant adult mice initially have increased β-cell function and mass (Shigeyama et al. 2008; Hamada 421 
et al. 2009) with age there is a decline in β-cell function and mass mediated by feedback inhibition of  422 
mTORC1 and the induction of autophagy (Shigeyama et al. 2008; Bartolomé et al. 2014). 423 
Interestingly, obese diabetic humans have increased circulating levels of BCAA and this is predictive 424 
of T2DM progression (Newgard et al. 2009; Fiehn et al. 2010; Wang et al. 2011b). Thus it is 425 
plausible that elevated BCAA may cause chronic activation of mTORC1 in β-cells. This could result 426 
in a critical switch from mTORC1 stimulating β-cell growth to causing β-cell dysfunction, death and 427 
the onset of diabetes. Moreover, it has recently been reported that increased amino acid flux mediated 428 
by increased AA transporter expression exacerbates ER stress induced β-cell death and diabetes in the 429 
Akita mouse (Krokowski et al. 2013). Hence although BCAA likely plays an important positive role 430 
in maintaining glucose homeostasis, chronic increase in circulating BCAA may be a critical 431 
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determinant in the development of type-2 diabetes. Although this report focuses on the role of LAT1 432 
in β-cell signalling and function, LAT2 and LAT4 were also found to be expressed in both clonal β-433 
cells and islets of Langerhans and thus are also likely to play important roles in the β-cell. 434 
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Figure legends 446 
 447 
Figure 1. System-L amino acid transporters are required for signaling to mTORC1 in INS1E 448 
cells. a Serum starved INS1E cells were incubated for 30min in EBSS (20mM glucose, 2mM L-449 
glutamine) supplemented with either 1x MEM essential amino acids (EAA) (+ System L-AAs) or 1x 450 
MEM EAA minus the System-L amino acid substrates (- System L-AAs) in the presence or absence 451 
of 100nM insulin +/- 2.5mM BCH as indicated. Proteins were resolved by SDS-PAGE, and Western-452 
blotted using antisera against the proteins indicated. The results are graphically represented below 453 
showing the mean + S.E.M for three independent experiments. ***, P < 0.001, **, P<0.01, *, P<0.05; 454 
compared with insulin plus System-L amino acids. (A.U. = arbitrary unit). b) Serum starved INS1E 455 
cells were incubated for 30min in EBSS (20mM glucose, 2mM L-glutamine) supplemented with 456 
either 1x MEM essential amino acids (EAA) and 100nM insulin The effect of the addition of BCH 457 
(+BCH) or the withdrawal of System-L amino acids ((-)L-AAs) on intracellular amino acid 458 
concentration was determined by HPLC analysis. The results are mean + S.E.M for five independent 459 
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experiments. *, P <0.05; and ***, P < 0.001 compared with control. c) L-[3H]-Leucine uptake (in the 460 
presence of 0.8mM leucine) in the absence (- BCH) or presence (+ BCH) of 2.5mM BCH. The results 461 
presented are the mean + S.E.M of 3 independent experiments. ***, P < 0.001 compared with control.   462 
 463 
Figure 2.  The system-L amino acid substrate leucine is required for signaling to mTORC1 in 464 
INS1E cells. a) Serum starved INS1E cells were incubated for 30min in EBSS containing 20 mM 465 
glucose, 2mM L-glutamine supplemented with either  1 x MEM EAA (+ System-L AAs) or 1x MEM 466 
EAA minus System-L amino acids ( - System-L AAs) in the presence or absence of each individual 467 
system-L amino acid substrate (single letter amino acid code) as specified. Where indicated, 100nM 468 
Insulin (insulin) was also included. b) BCH inhibits leucine-stimulated mTORC1 activation in INS1E 469 
cells. INS1E cells were pre-incubated in DMEM minus L-Leucine for 1 h. The cells were then 470 
incubated for a further 30 min in DMEM minus leucine supplemented with either 0.8mM or 0.4mM 471 
leucine in the presence or absence of 2.5mM BCH. c) Leucine stimulates mTORC1 in a dose-472 
dependent manner. INS1E cells were pre-incubated in DMEM minus L-leucine for 1 h, followed by 473 
30 min treatment in DMEM minus leucine supplemented with increasing concentration of L-leucine 474 
as indicated. Leucine concentration response curves and corresponding EC50 are shown below. The 475 
results presented are the mean (+/- S.E.M) of at least three independent experiments. d) INS1E cells 476 
were pre-incubated in DMEM minus L-Leucine for 1 h. The cells were then incubated for a further 30 477 
min in DMEM minus leucine supplemented with either 0.8mM leucine in the presence or absence of 478 
10µM nifedipine.  In all cases, proteins were resolved by SDS-PAGE, and Western-blotted using 479 
antisera against the proteins indicated. All results are representative of at least three independent 480 
experiments.  481 
 482 
Figure 3. The temporal kinetics of leucine-dependent mTORC1 activation.  INS1E cells were 483 
pre-incubated in a) DMEM containing 0.8mM L-Leucine or b) DMEM minus leucine for 1 h 484 
followed by the incubation in (a) DMEM minus leucine or (b) DMEM containing 0.8mM L-Leucine 485 
for up to 30 min. a and b) Proteins were resolved by SDS-PAGE and Western-blotted using antisera 486 
against the proteins indicated. The results are the mean + S.E.M for at least three independent 487 
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experiments. *, P <0.05; **, P <0.01; and ***, P < 0.001, compared with control (i.e. 0 min time 488 
point). c) Left 2 bars: INS1E cells pre-incubated in DMEM+0.8mM Leu for 1 hr followed by 489 
incubation in DMEM minus Leu for 10min; right 2 bars: pre-incubated in DMEM minus Leu for 1hr 490 
followed by incubation in DMEM+0.8mM Leu for 10min. The cells were harvested and the 491 
intracellular concentration of leucine determined by HPLC.  492 
 493 
Figure 4. System-L transporters play an important role in regulating islet signaling and 494 
function. Rat islets of Langerhans were incubated in DMEM minus L-Leucine for 1h prior to a 30 495 
min incubation in DMEM plus or minus 0.8mM Leucine in the presence or absence of 2.5mM BCH. 496 
a) Proteins were resolved by SDS-PAGE, and Western-blotted using antisera against the proteins 497 
indicated. Graphical representation of the results are shown below. b) Insulin Secretion Assay 498 
performed by ELISA on the test medium collected at the end of above treatment. c) Islets of 499 
Langerhans were incubated in RPMI supplemented with 0.2% FBS for 24h. The medium was 500 
replaced with DMEM minus leucine or DMEM containing 0.8mM leucine in the presence or absence 501 
of 2.5mM BCH for 48 h. 2µCi  [3H]-thymidine was added for the last 24h. d) Rat islets of Langerhans 502 
were incubated in DMEM minus L-leucine for 1h prior to a 30 min incubation in DMEM plus or 503 
minus 0.8mM leucine in the presence or absence of 2.5mM BCH. Cells were harvested for HPLC 504 
analysis and the intracellular leucine concentration determined as described in methods. e) L-[4,5-3H]-505 
Leucine uptake in the presence of 0.8mM leucine in either the presence (+BCH) or absence (-BCH)  506 
of 2.5mM BCH. All results presented are the mean + S.E.M for at least three independent 507 
experiments. ***, P < 0.001, **, P<0.01, *, P<0.05.  508 
 509 
Figure 5. LAT1 is highly expressed in primary islets. a) qPCR analysis of LAT1, LAT2, LAT3 and 510 
LAT4 expression in isolated rat islets of Langerhans expressed as fold change in expression of the 511 
target gene (LAT1, LAT2, LAT3 and LAT4) relative to the reference gene (18S RNA). The mean 512 
normalized expression (MNE) of the target genes was calculated using 2-ΔΔCT method. Expression 513 
values were multiplied by 106 for clarity of presentation. The results presented are the mean + S.E.M 514 
of three independent experiments. b) . Rat islets of Langerhans were transfected with siRNAs against: 515 
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CD98(SLC3A2) or scrambled siRNA as control. After 72 h the cells were incubated in  DMEM minus 516 
Leucine for 1 h, followed by the re-addition of 0.8mM Leucine for 30 min. Proteins were resolved by 517 
SDS-PAGE, and Western-blotted using antisera against the proteins indicated. The results are 518 
graphically represented below showing the mean + S.E.M for three independent experiments. ***, P 519 
< 0.001, **, P<0.01, *, P<0.05 (A.U. = arbitrary unit).   520 
 521 
Figure 6. LAT1 couples to mTORC1 signalling in islet cells. Rat islets of Langerhans were 522 
transfected with siRNAs against: a) LAT1 (Slc7a5) (INVITROGEN s132356) (siLAT1-A) or 523 
scrambled siRNA (siScr) as control; and b) LAT1 (Slc7a5) (Dharmacon, SMART POOL on 524 
TARGET) (siLAT1-B) or scrambled siRNA (siScr) as control. After 72 h the cells were incubated in 525 
DMEM minus Leucine for 1 h, followed by the re-addition of 0.8mM Leucine for 30 min. Proteins 526 
were resolved by SDS-PAGE and Western-blotted using antisera against the proteins indicated. The 527 
results are graphically represented below showing the mean + S.E.M for three independent 528 
experiments. ***, P < 0.001, **, P<0.01, *, P<0.05 (A.U. = arbitrary unit).  c and d) Quantification of 529 
LAT1 expression in dispersed rat islets by qPCR after 72 h of transfection with (c) LAT1 (Slc7a5) 530 
(Dharmacon, SMART POOL on TARGET)  or (d) (INVITROGEN s132356). Mean + S.E.M for 531 
three independent experiments. ***, P < 0.001, **, P<0.01, *, P<0.05 (A.U. = arbitrary unit).   532 
 533 
Figure 7. LAT1 is required for islet cell function and proliferation. Dispersed rat islets of 534 
Langerhans were transfected with siRNAs against: a)) LAT1 (Slc7a5) or scrambled siRNA as control. 535 
After 72 h the cells were incubated in DMEM minus Leucine for 1 h followed by the re-addition of 536 
0.8mM Leucine for 30 min. An Insulin ELISA assay from on media collected after treatments. b) 537 
Dispersed rat islets of Langerhans were transfected with LAT1 (Slc7a5) or scrambled siRNA as 538 
control and incubated for 72h. 1µCi/ml 3H-thymidine was added in the last 24 h.  539 
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